Anticoagulant counter ion impact on bioanalytical LC-MS/MS assays: Results from discussions and experiments within the European Bioanalysis Forum

Bioanalysis

Volumn 3, Issue 21, 2011, Pages 2393-2399

  Sennbro, Carl Johan ^a   Knutsson, Magnus ^b   Van Amsterdam, Peter ^c   Timmerman, Philip ^d  

^a Active Biotech Research AB   (Sweden)

^b Ferring Pharmaceuticals AS   (Denmark)

^c Chemical Design and Synthesis Unit   (Netherlands)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; COUNTERION; DRUG ADDITIVE;

ACCURACY; ANALYTIC METHOD; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; POLICY; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS; VALIDATION STUDY;

ANTICOAGULANTS; BLOOD CHEMICAL ANALYSIS; BLOOD SPECIMEN COLLECTION; CHROMATOGRAPHY, LIQUID; CONGRESSES AS TOPIC; EUROPE; HUMANS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 81055133503     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.239     Document Type: Article

References (12)

1. Ching SY, Prins AW, Beilby JP.Stability of ascorbic acid in serum and plasma prior to analysis.Ann.Clin.Biochem.39(5), 518-520 (2002). (Pubitemid 34983450)
2. Mei H, Hsieh Y, Nardo C et al.Investigation of matrix effects in bioanalytical high-performance liquid chromatography/tandem mass spectrometric assays: application to drug discovery.Rapid Commun.Mass Spectrom.17(1), 97-103 (2003). (Pubitemid 36019888)
3. Smeraglia J, Baldrey SF, Watson D.Matrix effects and selectivity issues in LC-MS/MS.Chromatographia 55(Suppl.1), S95-S99 (2002). (Pubitemid 34548117)
4. Viswanathan CT, Bansal S, Booth B et al.Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays.Pharm.Res.24, 1962-1973 (2007). (Pubitemid 47389236)
5. US FDA.Center for Drug Evaluation and Research.Center for Veterinary Medicine.Guidance for Industry - Bioanalytical Method Validation (2001).
6. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP).Guideline on Bioanalytical Method Validation (2011).
7. Bergeron M, Bergeron A, Furtado M et al.Impact of plasma and whole-blood anticoagulant counter ion choice on drug stability and matrix effects during bioanalysis.Bioanalysis 1(3), 537-548 (2009).
8. Savoie N, Booth BP, Bradley T et al.The 2nd Calibration and validation group workshop on recent issues in good laboratory practice bioanalysis. Bioanalysis 1(1), 19-30 (2009).
9. Marcelín-Jiménez G, Angeles-Moreno AP, Contreras-Zavala L et al.A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.Clin.Ther. 31(9), 2002-2011 (2009).
10. Sennbro CJ (on behalf of the European Bioanalysis Forum).Choice of anticoagulant and comparison of counter-ions - results from two EBF Surveys.Presented at: The EBF Open Symposium.Barcelona, Spain, 2 December 2010.
11. Sadagopan NP, Li W, Cook JA et al.Investigation of EDTA anticoagulant in plasma to improve the throughput of liquid chromatography-tandem mass spectrometric assays.Rapid Commun.Mass Spectrom.17(10), 1065-1070 (2003). (Pubitemid 36538200)
12. Sennbro CJ, Knutsson M, van Amsterdam P et al.Anticoagulant counter ion impact on bioanalytical LC-MS/MS based performance - additional validation required? Bioanalysis 3(21), 2389-2391 (2011).